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Abstract 
Introduction 
Hirschsprung’s disease (HSCR) and African degenerative leiomyopathy (ADL) are rare 
gastrointestinal disorders affecting neonates and young children. HSCR is characterised by the 
absence of intrinsic ganglion cells in the distal segment of the intestine; its aetiology has been 
linked to cellular and molecular mechanisms associated with the enteric nervous system (ENS) 
development, ADL on the other hand is a distinctive form of visceral myopathy (VSCM) of 
uncertain aetiology affecting enteric smooth muscles (ESM) of the distal intestine. Gut motility 
is a result of highly coordinated contractions by muscle layers, neural network and pacemaker 
intestinal cells of Cajal whose development are controlled by genetic factors.  
The aetiology of HSCR has been associated with 15 genes linked to ENS development 
meanwhile ADL has been linked to environmental factors. Actin gamma 2 (ACTG2) is a gene 
that encodes the ACTG2 protein which is involved in ESM development. Studying the ACTG2 
in HSCR patients may ascertain whether individuals affected by HSCR also display muscular 
dysfunction thereby providing a possible factor in the recurrence of dysmotility post-surgical 
resection. Additionally, ACTG2 has been identified as the genetic factor in VSCM pathology; 
therefore, the study may provide novel information regarding the genetic factors of ADL. 
 
Aim 
This project aims to study the genes associated with the development of enteric nervous system 
(RET, NRG1, SOX10, EDNRB) and smooth muscle cells (ACTG2) that contribute to HSCR and 
ADL in the South African neonate population. 
 
Methods  
Seventeen whole blood samples were collected from HSCR participants after informed 
consent; of which only 14 samples were included for genotyping and 9 samples were selected 
for RNA analysis based on the quality of extracted DNA and RNA respectively. Five whole 
blood samples were also collected from ADL patients after informed consent. RNA samples 
from the HSCR cohort were reverse transcribed and quantitative polymerase chain reaction 
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was performed.  DNA samples from HSCR and ADL samples were screened for variants in 
the ACTG2 exons through bidirectional Sanger sequencing. Novel variants were analysed in 
silico to ascertain their pathogenicity. 
 
Results and Discussion 
In both HSCR and ADL cohorts the variant K119E/R was observed in 64% (9/14) and 60% 
(3/5) of the study population respectively; K119E/R is likely to function as a disease modifier 
as it was also observed in the control samples six out nine individuals. Variants S345L and 
W357G in exon 10 with probable significant effect in the pathogenesis of ESM were identified 
in the HSCR cohort only. The ADL cohort had polymorphic intronic variants predicted to shift 
the exonic splice sites namely g>c -IVS12 exon 3 and c>t -IVS3 exon 5. Differential expression 
of ENS genes EDNRB, RET, SOX10 and NRG1 associated with ENS development in the HSCR 
cohort was not achieved due to experimental factors.    
 
Conclusion 
ACTG2 encodes an enteric smooth muscle γ-2 actin which plays a pivotal role in the contractile 
proteins of ESM, thus the data suggests that a muscular component may exist in HSCR 
aetiology that should be investigated further in vitro and provides further insights into genetic 
factors that may contribute to ADL pathogenesis.  
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Opsomming 
Inlieding 
Hirschsprung se siekte (HSCR) en Afrika-degeneratiewe leiomyopatie (ADL) is skaars gastro-
intestinale afwykings wat neonate en jong kinders raak. HSCR word gekenmerk deur die 
afwesigheid van intrinsieke ganglion selle in die distale segment van die dunderm; sy etiologie 
is gekoppel aan sellulêre en molekulêre meganismes wat verband hou met die ontwikkeling 
van die enteriese senuweestelsel (ENS). ADL, aan die ander kant, is 'n kenmerkende vorm van 
viscerale myopatie (VSCM) van onseker etiologie wat enteriese gladdespiere (ESM) van die 
distale dunderm beïnvloed . Gutmotiliteit is 'n gevolg van hoogs gekoördineerde kontraksies 
deur spierlae, neurale netwerk en pacemaker-intestinale selle van Cajal wie se ontwikkeling 
deur genetiese faktore beheer word. 
Die etiologie van HSCR is geassosieer met 15 gene wat verband hou met ENS-ontwikkeling, 
terwyl ADL gekoppel is aan omgewingsfaktore. Actin gamma 2 (ACTG2) is 'n geen wat kodeer 
vir die ACTG2 proteïen wat betrokke is by ESM ontwikkeling. Die studie van die ACTG2 in 
HSCR pasiënte kan vasstel of individue wat deur HSCR geraak word ook spierafwykings toon 
en sodoende 'n moontlike faktor in die herhaling van dysmotiliteit post-chirurgiese reseksie 
bied. Daarbenewens is ACTG2 geïdentifiseer as die genetiese faktor in VSCM patologie; 
daarom kan die studie nuwe inligting verskaf oor die genetiese faktore van ADL. 
 
Doel 
Hierdie projek poog om die gene wat verband hou met die ontwikkeling van die enteriese 
senuweestelsel (RET, NRG1, SOX10, EDNRB) en gladdespierselle (ACTG2) te bestudeer wat 
bydra tot HSCR en ADL in die Suid-Afrikaanse neonaatbevolking. 
 
Metodes 
Sewentien volbloedmonsters is na die ingeligte toestemming van die HSCR-deelnemers 
afgehaal; waarvan slegs 14 monsters vir genotipering ingesluit is en 9 monsters is gekies vir 
RNA-analise gebaseer op die gehalte van onttrek DNA en RNA onderskeidelik. Vyf volledige 
bloedmonsters is ook by ADL-pasiënte ingesamel na ingeligte toestemming. RNA monsters 
van die HSCR kohort was omgekeerde transkribeerde en kwantitatiewe polimerase 
kettingreaksie uitgevoer. DNA monsters van HSCR en ADL monsters is gesif vir variante in 
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die ACTG2 exons deur tweerigting Sanger volgorde. Nuwe variante is in siliko geanaliseer om 
hul patogeniteit te bepaal. 
 
Resultate en bespreking 
 
In beide HSCR- en ADL-kohorte is die variant K119E / R waargeneem in 64% (9/14) en 60% 
(3/5) van die studiepopulasie; K119E / R sal waarskynlik as 'n siekteveranderings funksie 
funksioneer, aangesien dit ook in die kontrolemonsters ses uit nege individue waargeneem 
word. Variante S345L en W357G in exon 10 met waarskynlike beduidende effek in die 
patogenese van ESM is slegs in die HSCR kohort geïdentifiseer. Die ADL-kohort het 
polimorfiese introniese variante voorspel om die eksoniese splytareas te verskuif, naamlik g> 
c -IVS12 exon 3 en c> t -IVS3 exon 5. Differensiële uitdrukking van ENS gene EDNRB, RET, 
SOX10 en NRG1 wat verband hou met ENS ontwikkeling in die HSCR kohort is nie bereik as 
gevolg van eksperimentele faktore nie. 
 
Afsluiting 
 
ACTG2 enkodeer 'n enteriese gladdespier γ-2 actien wat 'n sleutelrol speel in die kontraktiele 
proteïene van ESM. Die data dui daarop dat 'n spierkomponent bestaan in HSCR etiologie 
wat verder in vitro ondersoek behoort te word en verdere insigte in genetiese faktore wat kan 
bydra tot ADL patogenese. 
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CHAPTER 1 
1. Introduction 
1.1. Background 
Gut motility is a well-co-ordinated movement facilitated by a combination of enteric neurons, 
smooth muscle cells and interstitial cells of Cajal. These components function co-ordinately to 
assist in the transportation and absorption of nutrients, and the elimination of waste from the 
gastrointestinal tract (Burzynski et al., 2009; Schlieve et al., 2017). Disorders affecting 
gastrointestinal motility such as Hirschsprung’s disease and African degenerative 
leiomyopathy are part of gastrointestinal motility deficit spectrum, resulting from either 
neuropathic or myopathy deficit respectively. These debilitating diseases are prevalent in 
young children and have thus far proven to be problematic for both paediatricians and 
gastroenterologists alike; resulting from their ability to progress to a severe condition such as 
enterocolitis post successful resection surgery (Levitt et al., 2010).  
 
Affected patients rely on corrective surgery to alleviate the effects of the disorders; however, 
for some individuals the quality of life is reduced, and they may require repeated surgery 
throughout their life due to disease persistence (Friedmacher and Puri, 2011; Kessmann, 2006). 
The genetic basis of HSCR has been elucidated through research, which has assisted parents 
by genetic counselling. On the other hand, the persistence of dysmotility in some patients has 
led to the investigation of other environmental and genetic risk factors contributing to disease 
recurrence post resection surgery. The genetic insights into these gastrointestinal diseases 
tested in this study may provide a model for the development of novel treatment and disease 
management.  
 
1.2. Problem   statement  
A small number of HSCR patients are affected by recurrent motility defects following 
successful resection surgery, which further predispose to enterocolitis. Although the enteric 
nervous system genes namely (RET, GDNF, GFRα, EDNRB, SOX10, PSP etc.) have been 
extensively studied in HSCR cases; however, they do not provide sufficient information on the 
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possible cause of the morbidity persistence. Therefore, studying genes responsible for smooth 
muscle development such as ACTG2, which are the attachment area where ENS pass their 
current for contraction may provide information essential towards understanding the risk of 
recurrence. 
Further study of these smooth muscle gene (ACTG2) may also provide information regarding 
the molecular basis of African degenerative leiomyopathy; which is generally accepted as an 
acquired disease. In addition, cases of familial occurrences have been reported suggesting a 
possible genetic etiopathogenesis, hence comparing the smooth muscle gene variation between 
these gastro-motility diseases may provide vital information regarding the affected genes.   
 
Keywords:    Hirschsprung’s disease, Enteric nervous system, Enteric smooth muscle, African 
degenerative leiomyopathy
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CHAPTER 2 
 
2. Literature Review 
 
2.1. Hirschsprung’s disease 
Hirschsprung’s disease (HSCR) (OMIM 142623) has been labelled as one of the most 
understudied genetic disorders in the African population; although it has been reported to occur 
in 1:5000 live births in the Caucasian population  (Bahrami et al., 2018). Recent studies have 
shown that only 20-40% of neonates affected by HSCR in the African population have been 
diagnosed with the disorder compared to  90% diagnosis in European countries (Mabula et al., 
2014). HSCR is a congenital malformation of the distal gastrointestinal tract, resulting from 
the absence of intrinsic ganglion cells in the wall of the hind gut of affected patients (Eketjäll 
and Ibáñez, 2002; Iwashita et al., 1996). It is characterized by the functional obstruction of the 
bowel and failure to pass stool within the first 24 hours of life. This may be accompanied by 
severe constipation, colonic distention in neonates and enterocolitis in adults (Basel-Vanagaite 
et al., 2007; Garcia-Barceló et al., 2004; Mandhan, 2011).  
 
HSCR does not follow the Mendelian mode of inheritance and is a sex biased congenital 
anomaly with a male: female ratio of 4:1 (Amiel et al., 2008). It is commonly classified into 
two types depending on the extent of the aganglionosis of the affected colon, namely: short 
segment (S-HSCR) and long segment (L-HSCR). S-HSCR affects the recto-sigmoid region of 
the bowel, meanwhile L-HSCR extend beyond the recto-sigmoid region thus affecting the 
entire colon. Additionally, S-HSCR is the most common type of congenital aganglionosis 
observed in 80% of reported HSCR cases. Other forms of HSCR have been reported where the 
aganglionosis extend beyond the colon and affect the small intestine although these are rare. 
Total colon aganglionosis (TCA) occurs as a result of lack of ganglion cells on portions of the 
small intestine in addition to the colon (Alves et al., 2013). Rarely the aganglionosis affects 
both the entire colon and small intestine, this is classified as total intestine aganglionosis (TIA) 
(Amiel and Lyonnet, 2001).   
HSCR pathogenesis has been shown to be a consequence of the disruption of the normal 
development of the enteric nervous system (ENS). Therefore, its pathogenesis can be 
understood conceptually through the study of the cellular and molecular mechanisms of genes 
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associated with normal ENS development. The REarranged during Transfection (RET) proto-
oncogene is the major controlling signalling pathway of ENS development; with at least one 
RET allele alteration identified in individuals affected by HSCR (Amiel and Lyonnet, 2001; 
Gui et al., 2017; Julies et al., 2001). RET coding mutations have been reported in both familial 
and sporadic HSCR cases occurring at 50 and 15-35% respectively. Serra and colleagues 2009, 
reported that mutations also occur on the enhancer sequence on intron 1 which has a stronger 
predisposition to HSCR (Serra et al., 2009). The intronic alterations present in the form of two 
single nucleotide polymorphisms (SNPs) rs2506004 (SNP1) and rs2435357 (SNP2); the latter 
is known to disrupt the binding site of transcription factor SOX10  subsequently affecting the 
expression of RET (Kapoor et al., 2015; Moore and Zaahl, 2012; Núñez-Torres et al., 2011).  
 
2.1.1. RET  
REarranged during Transfection (RET), which encodes a receptor tyrosine kinase (RTK) maps 
to chromosome 10q11.2 (Taccaliti et al., 2011) comprises of 21 exons. RET is a 1114 
transmembrane amino acid; its structure consists of the extracellular cadherin-like and 
intracellular tyrosine domains and a cysteine rich region. These components are all essential 
for RET phosphorylation and downstream signalling (Amiel and Lyonnet, 2001; Wagner et al., 
2012) (figure 2.1). RET binds growth factor receptor of the glial cell line derived neurotrophic 
factor (GDNF) on neural crest cells (Ibáñez, 2013; Santoro et al., 2004); which functions to 
promote ENS development.  
 
The alternative splicing of RET generates its three isoforms namely the long, intermediate and 
short RET isoforms; which differ variably by amino acid length at the C-terminus. These 
isoforms are commonly referred to as RET51, RET43 and RET9 (Arighi et al., 2005) 
(figure2.1). RET9 and RET51 are the two main isoforms,  they share tyrosine (Y) residues 
except the Y1096 which is specific to RET51 (Ibáñez, 2013; Little, 2015); the phosphorylation 
of the Y residues trigger the activation of RET signalling pathways. 
 
RET is reported to be responsible for triggering three signalling pathways; the mitogen 
activated protein kinase (MAPK), the phospholipase C- gamma (PLCγ) and the 
phosphatidylinositol-3 kinase (PI3K)  pathways (Ibáñez, 2013; Lundgren et al., 2012). The 
roles of the MAPK and PI3K pathways in the nervous system involves the promotion of neurite 
outgrowth and survival of neurons (Sariola and Saarma, 2003).  The PLCγ pathway  plays a 
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crucial role in  regulation of the intracellular calcium ion levels (Lundgren et al., 2012; McCain, 
2013; Sariola and Saarma, 2003). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1: The structure of RET showing the different domains of RET including the splicing 
isoforms RET9 (black), RET43 (brown) and RET51 (blue). Adapted from (Phay and Shah, 
2010) Copy Right license 4474300195937 (Clinical Cancer Research)  
 
2.1.1.1. The RET and GDNF pathway 
Under normal cell growth, RET is exclusively activated by the binding of a soluble ligand 
complex; composed of the glial cell line derived neurotrophic factors (GDNF) family ligands 
and the co-receptor of the GDNF family receptor α (GFRα) (Anderson et al., 2013). The GDNF 
ligand family include; glial cell line derived neurotrophic factor (GDNF), artemin (ARTN), 
neurturin (NTRN) and persephin (PSPN) (Mason, 2000; Wagner et al., 2012). GDNF receptors  
require gylcosylphosphatidylinositol (GPI) anchored co-receptors to interact with RET on the 
cell surface, commonly known as GDNF family receptor α (GFRα 1-4) (figure 2.2).   
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Activation of RET is essential for the survival of pre-enteric neural crest cells in the foregut 
mesenchyme (Natarajan et al., 2002), resulting in mature enteric neural crest cells and also 
provides a proliferative signal to the enteric neural crest cells.  GDNF, NTRN, ARTN and 
PSPN ligands bind GPI anchored receptors GFRα1, GFRα2, GFRα3 and GFRα4 respectively; 
in order to signal through RET (figure 2.2) (Wagner et al., 2012). Multiple downstream 
pathways are stimulated by the activation of RET, resulting in the promotion of cell growth, 
survival, proliferation and differentiation.  
 
 
 
 
 
 
 
 
 
 
Figure 2.2: A schematic diagram of RET activation. The GDNF family ligands and their 
respective GPI anchored co-receptors on the lipid raft form a complex and each bind to RET 
and activate it. Taken from (Airaksinen and Saarma, 2002). Copy Right licence 
4446391044778 (Elsevier and Copyright Clearance Center). TK= Tyrosine Kinase 
 
One of RET ligands, GDNF known to be the main ligand in RET activation, its gene maps to 
chromosomes 5p12-13.1. GDNF has been reported to be essential for the survival of neuronal 
cells from both the peripheral nervous  (PNS) and central nervous systems (CNS) (Taraviras et 
al., 1999). During ENS development, GDNF has been reported to be involved in directing the 
enteric neural crest cells (ENCC) during their caudal migration to the entire gut (Holschneider 
and Puri, 2007); while acting as a chemoattractant to the ENCC. Additionally, GDNF functions 
to give proliferative signals to the ENS progenitors in the colon (Mundt and Bates, 2010), and 
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also plays a pivotal role in preventing NCCs from early differentiation into neurons (Anderson 
et al., 2013) supporting its role in gene regulation.  
Although studies have shown that mutations occurring solely in the GDNF rarely contribute to 
reduced RET activation (Borghini et al., 2002); a characteristic known to predispose to the 
aganglionosis of the distal bowel. Numerous studied have demonstrated that GDNF mutations 
which result in HSCR phenotype are a consequence of a combination of mutations in both 
GDNF and the susceptibility locus RET. 
 
2.1.2. Other genes 
Hirschsprung’s disease has been classified as a multigene disease with the RET proto-oncogene 
described as the major susceptibility gene; however other genes also play a role in its 
pathogenesis which account for at least 7% to the disease susceptibility. Fourteen HSCR 
susceptibility genes in addition to the RET proto-oncogene have been identified. These genes 
belong to three categories: (i) genes involved in the activation of the RET pathway (RET, 
GDNF, GFRα, L1CAM, NTN and PSP), (ii) genes implicated in the EDNRB pathway (EDNRB, 
EDN3, ECE-1, NRG1 and NRG3) and (iii) RET/EDNRB pathway transcription factors 
PHOX2B, ZFXH1B, PAX3 and SOX10.  
The downregulation of these genes negatively affect their role in neurite migration, 
localization, proliferation and differentiation; which are essential for ENS development during 
embryogenesis. Alves and colleagues 2013, conducted research which outlined the correlation 
between RET, SOX10, EDNRB and NRG1 within cells during embryogenesis (figure 2.3), 
which this study has selected to analyse further in real time indicated by red circles on  figure 
2.3 (Alves et al., 2013).  
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Figure 2.3:  Schematic diagram generated by Alves and colleagues demonstrating HSCR genes 
of interest RET, EDNRB, SOX10 and NRG1 interactions within the cell through their pathways. 
Taken from (Alves et al., 2013) Copy Right licence 4459281032094 (Elsevier and Copyright 
Clearance Center). ENCDC=enteric neural crest-derived cells 
 
 
2.1.2.1. EDNRB  
The endothelin pathway is the second most common pathway linked to HSCR development 
and its phenotype (Sánchez-mejías et al., 2010). It includes genes such as endothelin cleaving 
enzyme 1 (ECE1), endothelin 3 (EDN3) and endothelin receptor type-B (EDNRB) accounting 
for at least 3-7% of reported HSCR mutations (Barlow et al., 2003). EDNRB maps to 
chromosome 13q22 that is activated by the binding of mesenchymally-synthesized EDN3. 
EDN3 is the result of enzymatic cleavage of the inactive intermediate EDN by ECE1 (Saldana-
Caboverde and Kos, 2010). 
Research has demonstrated that EDNRB is responsible for the formation of  embryonic cells 
with different fates post embryonic development, such as enteric cells and produces 
melanocytes (Barlow et al., 2003; Goldstein et al., 2013; Mccallion and Chakravarti, 2001; 
Saldana-Caboverde and Kos, 2010); which are precursor cells that produce the pigment 
melanin. In addition, EDNRB is also involved in preventing the early differentiation of the 
neural crest precursor cells through timed regulation that maintains them in a proliferative state 
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during their migration to the distal portion of the digestive tract (Goldstein et al., 2013; Nagy 
and Goldstein, 2006). 
 
2.1.2.2. SOX10  
The multipotent sex determining region Y box 10 (SOX10) forms part of a large group of 
transcription factors; comprising 466 amino acids. SOX10 forms part of a family of genes with 
a highly conserved mobility group DNA binding domain in addition to a C-terminal domain 
(Sánchez-Mejías et al., 2010). It is essential for the development of both melanocyte and neural 
crest cells (Han et al., 2018). SOX10 function in the ENS development include neurite 
proliferation, migration and differentiation (Holschneider and Puri, 2007).  
SOX10 is also involved in the transcriptional regulation of both RET and EDNRB (Lake and 
Heuckeroth, 2013). As a consequence of its role in regulation of both genes; it has been reported 
to be an important ENS transcription factor. Sánchez-Mejías and colleagues 2010, reported that 
current research has not identified isolated SOX10 mutations responsible for HSCR morbidity 
(Sánchez-Mejías et al., 2010; Sham et al., 2001). However, SOX10 mutations are associated 
with syndromic type 4 Waardenburg syndrome-HSCR known to have a high HSCR penetrance.  
 
2.1.2.3. NRG1 
A member of the neuregulin family, neuregulin1 (NRG1) is an important ENS maintenance 
gene specifically involved in the formation of synapses, differentiation of nerve cells and the 
outgrowth of neurites (Barrenschee et al., 2015). NRG1 functions as a signalling glycoprotein 
which forms a heterodimeric complex with ErbB2/ErbB3 receptor tyrosine kinases (Kapoor et 
al., 2015). Similar to RET intronic SNP1 and SNP2, NRG1 has risk variants on intron 1 known 
to have a higher predisposition effect to HSCR namely rs16879552 and rs7835688 (Gui et al., 
2017; Jiang et al., 2017; Tang et al., 2011). Additionally, NRG1 coding mutations have been 
observed in at least 6% of HSCR cases (Alves et al., 2013). It has been further reported that 
HSCR predisposition is increased by the concurrence of both RET and NRG1 intronic SNPs 
(Gui et al., 2017).   
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2.1.3. Development of the enteric nervous system 
ENSis a component of the PNS made up of neurons and glia that form an interconnected 
network of enteric ganglia comprised of an outer and inner plexi; commonly known as 
myenteric and submucosal plexi respectively (Barlow et al., 2008) (figure 2.4). The plexi are 
located within the gut wall muscle layers; the myenteric plexus is located between the circular 
and longitudinal portion of the muscle layers and can be found throughout the digestive tract 
(Mills and Stappenbeck, 2013).  Meanwhile the submucosal plexus is exclusively located in 
the small and large intestine (Goldstein et al., 2013; Heanue and Pachnis, 2007) under the 
submucosal layer (Figure 2.4). The ENS functions to co-ordinately regulate intestinal motility 
(transportation of water and electrolytes), secretion, nutrient absorption and blood flow  
through the activation of its intrinsic reflexes (Goldstein et al., 2013). Subsequently 
contributing to the maintenance of the lumen and gut wall by microbiota composition 
constraining; a role reported to assist in maintaining commensal microbial communities (Rolig 
et al., 2017), thereby promoting a healthy gut.   
 
 
 
 
 
 
 
 
Figure 2.4: Cross section of the intestine showing the organization of the PNS plexi and the 
musculature of the intestinal walls. Adapted from (Furness et al., 2014). Copy Right license 
4467570350306 (Copyright Clearance Springer eBook) 
 
During embryogenesis neural crest-derived (NC) cells invade the bowel and migrate recto-
caudally into the colon; the migration is coupled with extensive proliferation and differentiation 
of NC into neurons and glia (Lake and Heuckeroth, 2013; Nagy and Goldstein, 2006). The 
neurons and glia subsequently condense into ganglia forming a network of active neurons and 
glia in the distal bowel. During week 7 of gestation the vagal portion of the neural tube gives 
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rise to vagal ENS progenitors known as pre-enteric neural crest cells (pENCC); which 
subsequently invade the mesenchyme (Vandewalle et al., 2005; Wallace and Burns, 2005).  
The invasion of the pENCCs into the mesenchyme is facilitated by the expression of 
transcription factor PHOX2B and the receptor tyrosine kinase RET (Burzynski et al., 2009; 
Laranjeira and Pachnis, 2009). The pENCCs migrate dorsally thereby inducing the expression 
of PHOX2B and RET; once in the mesenchyme, the cells are therefore known as enteric neural 
crest cells (ENCC). RET and SOX10 initiate the migration of the cells recto-caudally; where 
SOX10 also functions as ENCC marker while maintaining the cells in progenitor state (Butler 
Tjaden and Trainor, 2013). The progenitor arrest of ENCC enables the colonization of the 
entire gastrointestinal tract ultimately giving rise to the ENS. 
Due to this well coordinated migratory and differentiation, RET and the other developmental 
genes are essential to the development of the ENS. In addition to migration, RET signalling 
during embryogenesis supports the survival, neuronal differentiation, proliferation and 
colonization of ENS precursors and neurite growth. The successful colonization of NC in the 
bowel result in the ability to control peristaltic and secretory activity of the gut wall (Natarajan 
et al., 2002). Failure of NC to effectively colonize the bowel has clinical implications that lead 
to the aganglionosis of the ENS; consequently, causing diseases that affect gastrointestinal 
motility such as Hirschsprung’s disease.  
 
2.1.4. Disease Aetiology 
2.1.4.1. RET deactivation 
Loss of function or the inactivation of RET leads to the aganglionosis of the ENCC; 
subsequently causing the aganglionosis of the distal portion of the intestine which clinically 
manifest as HSCR. It has been reported that both germline point mutations (deletion, insertion 
and substitution) and non-coding mutations occurring on  RET  lead to a partial loss of function 
phenotype (Jannot et al., 2013; Myers et al., 1999). These mutations confer a cell type specific 
decrease in  functional protein on the cell surface (Wagner et al., 2012); resulting in the 
inactivation of RET.  
RET inactivation which results in HSCR disease occurs as a consequence of at least one of four 
mechanisms (Kurokawa et al., 2003; Takahashi, 2001): 
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1. Incorrect folding of RET subsequently leading to the impairment of RET cell surface 
expression. 
2. Mutation in the kinase domain of RET, that leads to the termination of the RET kinase 
activity. 
3. Impairment of the binding adaptor proteins as a result of mutations in the carboxy-
terminal tail. 
4. Mutations in the kinase domain of RET which reduce the activation of PLCγ pathway.  
As a functional consequence of RET inactivation, migration of neural crest cell during 
embryonic development is disrupted leading to congenital aganglionosis of the colon (Liang et 
al, 2014). ENCCs undergo apoptotic cell death resulting in the elimination of ENS precursors 
from the gastrointestinal tract (Liang et al., 2014). RET inactivation occurs in the absence of 
the GDNF-GFRα ligand complexes responsible for activating RET in addition to a variety of 
frame-shift, missense and nonsense mutations observed in the coding sequence (Kurokawa et 
al., 2003). 
 
2.1.4.2. RET activation 
In contrast, gain of function mutation which result from ligand-independent constitutive 
activation of RET is responsible for  development of multiple endocrine neoplasia (MEN) type 
2 A and B (MEN2A and MEN2B) cancers (Santoro et al., 2004; Wagner et al., 2012). MEN 
displays an autosomal dominant mode of inheritance (Lundgren et al., 2012); characterized by 
medullary thyroid carcinoma (MTC) including familial MTC (FMTC). Wild type activation of 
RET occurs in the presence of a multi-protein ligand complex comprising of GDNF ligands 
and their co-receptors GFR-α (Takahashi, 2001).  
Mutations responsible for MEN and MTC cancers occur in the cysteine rich (C-rich) portion 
of RET (Arighi et al., 2004). In this C-rich region a substitution of one of the highly conserved 
RET cysteine residues results in an unpaired cysteine; as a consequence this molecular 
modification enables the constitutive activation of RET (Arighi et al., 2005; Santoro and 
Carlomagno, 2013). These mutations are classified into two groups based on the part of the 
RET proto-oncogene they affect; those affecting the tyrosine kinase domain accounting for 
MEN2A and FMTC pathogenesis and those affecting the extracellular domain which are 
associated with MEN2B pathogenesis (Arighi et al., 2005; Wagner et al., 2012). 
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2.1.5. Comorbidities 
2.1.5.1. Down’s syndrome 
Frequently HSCR occurs with other genetic disorders; the common examples are Down’s 
syndrome (DS), Mowat-Wilson Syndrome, and Waardenburg syndrome (WS) in the affected 
patients. DS is the most common genetic disorder associated with HSCR; Heuckeroth 2015,  
reported that at least 2-10% of neonates with DS also harbour HSCR mutations (Heuckeroth, 
2015). Furthermore, research suggests that mutations in chromosome 21 increase the affected 
patients’ susceptibility to HSCR (Jannot et al., 2013). DS contributes to HSCR aetiology with 
an estimated 40% risk factor (Friedmacher and Puri, 2013; Jannot et al., 2013). Themajority of 
the RET mutations observed in patients affected with a combination of DS-HSCR occur in the 
non-coding polymorphism of the RET proto-oncogene enhancer element on intron 1 which 
affects the SOX10 binding site. 
 
2.1.5.2. Type 4 Waardenburg syndrome 
Mutations in EDNRB have been reported to play a role in the development of the type 4 
Waardenburg syndrome (WS4) in addition to aganglionosis of the colon, also referred to as 
Shah-Waardenburg syndrome. WS4 is a neurocristopathy characterized by sensorineural 
hearing and hair loss, skin and iris hypopigmentation in addition to HSCR. Nonetheless, the 
prevalence of WS associated with HSCR is rare; only occurring in only 4 in 1 million of 
reported cases (Karaca et al., 2009; Mahmoudi et al., 2013). The pathogenesis of WS4 involves 
other ENS genes such as SOX10 and the EDNRB ligand EDN3 (Amiel and Lyonnet, 2001), 
although the mechanism of action is not fully understood. 
 
2.2. African Degenerative Leiomyopathy  
Chronic intestinal pseudo-obstruction syndromes (CIPOs) include a variety of rare disorders 
affecting the motility of the gastrointestinal tract and peristalsis. This group of disorders such 
as hollow visceral myopathy (HVM) and megacystis microcolon intestinal hypoperistalsis 
syndrome (MMIHS) affect different parts of gut wall muscles (Matera et al., 2016; Moore et 
al., 2002); the former is associated with the pathogenesis of the distal gut. African degenerative 
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leiomyopathy (ADL) is a distinct form of visceral myopathy (VSCM) also known as Bantu 
pseudo-Hirschsprung’s disease (OMIM 155310) (Rode et al., 1992). ADL is prevalent in the 
Black African population; mainly those residing in the Southern, East and Central Africa. 
ADL is an enteric smooth muscle dysmotility disorder characterized by the impairment of the 
gastrointestinal propulsion without myenteric neuronal pathogenesis (Lehtonen et al., 2012). It 
consequently results in abdominal pain and enlargement, impaired nutrient absorption which 
leads to malnutrition, distention and sometimes leads to death (Klar et al., 2015; Rensburg et 
al., 2012). Chitnis and colleagues further reported that ADL progressively affects the 
gastrointestinal and genitourinary systems (Chitnis et al., 2011). In addition, ADL occasionally 
display the inherent ability to progress proximally from the distal bowel into the small intestine; 
resulting in some patient relying on total parenteral nutrition. 
 
2.2.1. Genetic aetiology of ADL 
Previously, it was generally accepted that ADL was  an acquired myopathic disorder with 
varying onset from birth to later in childhood (Halim et al., 2016). Its aetiology was linked only 
to environmental toxins coupled with poor nutrition; known to progressively degenerate the 
distal gut smooth muscle walls (Moore et al., 2002). Van Rensburg and colleagues 2012, 
prospectively studied RET variants in a rare familial case of ADL with the aim of providing 
insight regarding a molecular basis of the disease (Van Rensburg et al., 2012); from which 
numerous RET variants were identified.  
ADL often occurs sporadically, displaying an autosomal dominant pattern (Klar et al., 2015) 
whereas in the rare familial cases it displays heterozygosity with autosomal recessive 
patterning (Moreno et al., 2016). Although its genetic aetiology has not yet been elucidated; 
studying the actin and/ or myosin genes which have been associated with mutations in VSCM 
may aid in furthering the study towards the molecular basis of ADL. Mutations associated with 
smooth muscle actin and myosin in VSCM patients have been extensively studied under 
developing research.  
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2.2.1.1. ACTG2 
Actins are highly conserved family of proteins which form part of the cytoskeleton and exists 
in three isoforms, namely alpha (α), beta (β) and gamma (γ); each isoform has an essential 
function in gut motility. The β and γ isoforms especially play a role in the mediation of cell 
motility and form part of the cytoskeleton maintenance components (Sonnemann et al., 2006). 
Actin-γ-2 (ACTG2) is a smooth muscle gene encoding the γ-actin isoform, commonly known 
to be exclusively expressed in the urogenital and intestinal tracts of the enteric smooth muscle 
cells (Halim et al., 2016; Milunsky et al., 2017a). Meanwhile the α- and β- isoforms are found 
throughout the eukaryote cells as part of the cytoskeleton.  
ACTG2 on chromosomal position 2p13.1 is essential for distal gut motility which facilitate the 
accurate contractile motion of the smooth muscle cells responsible in aiding nutrient absorption 
and digestion  (Matera et al., 2016). It consists of 10 exons of which 8 (exons 3-10) undergo 
translation, mutations that occur in ACTG2 exons have been associated with various enteric 
muscular diseases such as MMIHS, VSCM and CIPO (Halim et al., 2016; Ravenscroft et al., 
2018; Wangler et al., 2014).   
 
2.2.1.2. MYH11 
Intestinal walls are lined by thick filaments known as myosin which are organized in a 
hexametric orientation in the lumen (Huang et al., 2018). Myosins are organized within the 
longitudinal and circular muscles as shown in figure 2.4; myosin proteins form part of the 
smooth muscle’s major contractile and cell movement mechanisms. The gene responsible for 
encoding the myosin protein is known as myosin heavy chain 11 (MYH11) with a 16p13.11 
chromosomal location (Kuang et al., 2011). MYH11 is known as one of the single genes that 
encodes four transcripts resulting in the SM1, SM2 isoforms at the carboxyl terminus and 
SMA, SMB isoforms at the amino terminus (Babu et al., 2000); this occurs through alternative 
splicing. The structure of MYH11 is composed of the head region which interacts with actin 
and a tail region which interacts with other myosin tails. 
 
2.2.2. Enteric smooth muscle development 
Enteric muscle cell fibres are primarily composed of both actin and myosin filaments; with 
actin forming the thin filaments whereas the thick filaments make up the myosin (Kwartler et 
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al., 2014). In humans, the differentiation of the enteric smooth muscle cells (SMCs) during 
intestinal organogenesis is a process known to occur simultaneously with ENCC colonization 
(Graham et al., 2017). Although the SMC is formed independently from the neuronal network; 
it’s contractile mechanism has been reported to be regulated by the ENS and interstitial cells 
of Cajal (ICC) (Bourret et al., 2017; Le Guen et al., 2015; Sanders et al., 2012). ENS provide 
sufficient current for the generation of contractile action of the smooth muscles. SMC plays an 
essential role in the gastrointestinal tract as the last effector of contraction in the hindgut and 
excretion of waste from the stomach (Goldstein et al., 2016). Consequently, the impairment of 
SMC leads to diseases of hindgut hypomotility without aganglionosis. Furthermore, the outer 
longitudinal muscle layer (figure 2.4) is the portion of the intestinal wall acutely affected by 
enteric smooth muscle degeneration (Lehtonen et al., 2012).  
 SMC is formed from the mesenchyme which arises from the splanchnic mesoderm; these 
undifferentiated cells elongate, cluster and migrate rostro-caudally during organogenesis 
(Bourret et al., 2017; Wallace and Burns, 2005). They express α-smooth muscle as an initial 
marker of cell differentiation; a process  subsequently followed by the expression of γ-smooth 
muscle actin and smooth muscle protein 22 (Bourret et al., 2017; Faure et al., 2015; Graham et 
al., 2017). The expression of γ-smooth muscle actin and smooth muscle protein 22 signals that 
the cells have entered a determined phase. These determined cells enter a phase of 
differentiation mainly characterized by the expression of smooth muscle contractile proteins 
namely Calponin and Caldesmon (McKey et al., 2016). The expression of the contractile 
proteins marks the completion of the SM development during organogenesis.  
 
2.3. Therapeutic measures 
The current disease management available for HSCR involves corrective surgery employing 
the endorectal pull-through techniques (Friedmacher and Puri, 2011). These techniques are 
carried out by the removal of the aganglionic bowel segment and restoring functionality by 
joining the remaining normal bowel to the rectum. The commonly used operating techniques 
such as Duhamel’s, Swenson’s and Soave’s pull-through operations are regarded as an 
advancement from the usually invasive and time consuming rectosigmoidectomy and rectal 
myotomy (Kasai et al., 1971). The outdated techniques were often preceded by a preliminary 
colostomy or ileostomy months prior the operation (Somme and Langer, 2004). In contrast,  
the current Duhamel’s, Swenson’s and Soave’s pull-through techniques have improvements 
such as short hospitalization, one-step procedure and reduced stoma morbidity (De La Torre 
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and Langer, 2010; Georgeson and Robertson, 2004; Levitt et al., 2010). The improved 
techniques were first described in the 1980s  with minimal use of laparoscopy (De La Torre 
and Langer, 2010).   
Similarly, ADL requires abdominal surgery that may include the following procedures; 
laparoscopy assisted, ileostomy or gastrostomy procedures (Milunsky et al., 2017b) to alleviate 
the effects of the motility deficit; however, these do not always restore normal bowel function.  
Although surgical resection of the distal tract is currently the accepted method used for both 
HSCR and ADL remediation; some patients may  experience residual aganglionosis post-
surgery (Khong and Malcomson, 2015). Kessmann and colleagues 200, reported that 10-34% 
of HSCR patients whom have undergone successful resection surgery still present with 
persistent gastrointestinal defects throughout life; leading to enterocolitis or colonic rupture 
(Kessmann, 2006; Khong and Malcomson, 2015). As a result of such complications; close 
monitoring of patients post-surgery is recommended.  
We hypothesize that the persistence of the dysganglionosis may be a result of both ENS and 
SMC pathogenesis contributing to the HSCR phenotype. In this study we analyse the 
association between SMC genes and recurrent HSCR by comparing the variants ACTG2 
between HSCR and ADL patients. Further studying the expression of the genes associated with 
ENS development. 
 
2.4. Aim  
This project aims to study the genes associated with the development of enteric nervous 
system (RET, NRG1, SOX10, EDNRB) and smooth muscle cells (ACTG2) that contribute 
to HSCR and ADL in the South African neonate population. 
 
2.5. Objectives 
1. Analyse the differential expression of RET, NRG1, SOX10, EDNRB in HSCR cohort. 
2. Screening of ACTG2 in HSCR sample set. 
3.  Prospectively analyse ADL sample set for variants in ACTG2.  
4. Comparing ACTG2 variants between HSCR and ADL patients. 
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CHAPTER 3 
3. Materials and Methods 
3.1. Patient recruitment 
Ethical approval for the research project was granted by the Stellenbosch University Human 
Research Ethical Review Committee; ethical reference C2001/019. For the HSCR cohort, 
whole blood samples were collected pre-surgery with informed consent from 17 participants 
with histologically confirmed HSCR and nine non-HSCR controls at the Tygerberg Children’s 
Hospital. For the ADL cohort whole blood samples were collected from five histologically 
confirmed ADL patients; three participants from Pietermaritzburg Medi-clinic and two 
participants from Red-Cross Children’s Hospital patient demographics are outlined in table 
3.1. Non-HSCR control samples were not age matched; for minor participants the informed 
consent was given by a parent or legal guardian. Additionally, 8 negative control samples for 
Real Time-quantitative Polymerase Chain Reaction (RT-qPCR) were obtained with informed 
consent from the TB Meningitis study; ethical reference N16/11/142. The HSCR samples were 
used for both RNA and DNA analysis. 
 
Table 3.1: Patient demographics of the HSCR and ADL cohort  
Disease Age range Gender 
HSCR 2weeks-5years 14 males, 3 females 
ADL 10-24years 4 males, 1 female 
 
3.2. Gene selection 
The genes used for the RT-qPCR study were selected based on their protein-protein interaction 
based networks using GENEMania interaction database https://genemania.org/ .  
 
3.3. RNA extraction 
Ribonucleic Acid (RNA) extraction is an essential technique in molecular biology studies 
which uses refined processes to isolate RNA out of biological material such as blood. The 
process should be carried out timeously and in an environment that is specially prepared for 
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the isolation by using RNase degrading agents to wipe down surfaces and remove readily 
available RNases. There are various methods of isolation which include organic, spin basket 
format, direct lysis and magnetic particle methods (Vomelová et al., 2009). The protocol 
selected for the purpose of this study used the spin basket format method which uses membrane 
filters to separate RNA from biological matter. 
Total RNA was extracted from fresh whole blood using the QIAamp® RNA Blood Mini kit 
(Qiagen, Venlo, Netherlands) according to the manufacturer’s instruction. Each blood sample 
was transferred in 0.5 ml, 1.5 ml or 1 ml volume into a 15 ml falcon tube containing buffer EL; 
measured as 5 times the starting blood volume. Samples were incubated on ice for a maximum 
period of 15 minutes; followed by centrifugation with centrifuge 5810R (Eppendorf Hamburg, 
Germany) at 1890 rpm for 10 minutes at 4oC. The supernatant was discarded and buffer EL 
was added to the pellet in a measure of 2 volumes of the starting blood sample; the tubes were 
vortexed briefly and samples were centrifuged at 1890 rpm for 10 minutes at 4oC. The 
supernatant was discarded; and the pellet was re-suspended in buffer RLT containing 0.1% 2-
mercaptoethanol. The resulting lysate was transferred into a QIAshredder spin column in a 2ml 
collection tube; each sample was centrifuged with centrifuge 5424 (Eppendorf, Hamburg, 
Germany) at 14 000 rpm for 2 minutes.  
Following centrifugation, the QIAshredder spin column was discarded and the lysate was 
collected; to which 1 volume of 70% ethanol was added and mixed by pipetting.  The lysate 
was carefully transferred into a new QIAamp spin column in a 2 ml collection tube; the samples 
were centrifuged at 10 000 rpm for 15 seconds. The collection tube and supernatant were 
discarded; and the spin column was placed into a new 2ml collection tube.  
Buffer RW1 was added in a measure of 350μl into the column and the sample was centrifuged 
for 15 seconds at 10 000 rpm; the supernatant was discarded, and the tube was reused. A DNase 
digestion master mix (50 μl of 2X DNase 1U/L buffer, 8 μl of reconstituted DNase, 10 μl 
Manganese Chloride solution and 32 μl Nuclease free water) was prepared separately. The 
DNase master mix was aliquoted into each tube in 100 μl volume; the samples were incubated 
at room temperature for 15 minutes.  
Following incubation, 350 μl of buffer RW1 was added onto the column and the samples were 
centrifuged at same conditions as the previous step. The resulting supernatant was discarded 
together with the collection tube and the column was placed into a new collection tube. Buffer 
RPE was added into the column in a volume of 500 μl and the tubes were centrifuged at 10 000 
rpm for 15 seconds; the supernatant and collection tube were both discarded.  The column was 
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placed into a new collection tube. The previous step was repeated with centrifugation 
conditions set at 14 000 rpm for 3 minutes; thereafter the supernatant and collection tube were 
discarded and the column was placed into a new collection tube.  
The tube was centrifuged at 14 000 rpm for 1 minute and the column was placed into a clean 
1.5 ml microfuge tube. RNase- free water was added onto the centre of the column to a 
maximum volume of 50 μl; the tube was incubated at room temperature for 5 minutes and 
thereafter it was centrifuged at 10 000 rpm for 1 minute. Total RNA quantity and integrity were 
measured on the Nanodrop ND 1000 Spectrophotometer (Thermo Fisher Scientific, Weltham, 
Massachusetts, United States) and Agilent® 2100 Expert Bioanalyzer™ (Agilent 
Technologies, Santa Clara, California, United States) with the Agilent® RNA 6000 Nano 
system at the Central Analytical Facility (CAF), Stellenbosch University all samples were 
stored at -80oC. 
 
3.4. DNA extraction 
Deoxyribonucleic Acid (DNA) extraction is also essential like the isolation of RNA; however, 
DNA is very stable and robust compared to RNA, as such it does not require immediate 
isolation. DNA isolation employs numerous methods which include solid phase, Chelex or 
organic extractions (Elkins, 2013). All these methods act by isolating DNA from biological 
samples and making it readily available for downstream processing. In this study organic 
extraction method was employed to extract DNA from whole blood.  
Genomic DNA was extracted from whole blood using an adaptation of the Miller et al 1988 
protocol. Genomic DNA was extracted by a combination of two techniques: salt lysis and 
alcohol precipitation. Red blood cell (RBC) lysis was carried out by transferring 500 μl of 
blood sample into 2 ml Eppendorf tube containing 1ml cold lysis buffer (0.155 M NH4CL, 0.01 
M KHCO3 and 0.0001 M EDTA); the solution was briefly vortexed and then centrifuged with 
centrifuge 5424 (Eppendorf, Hamburg, Germany) at 14 000 rpm for 15 minutes. The 
supernatant was carefully discarded and another 1 ml of cold lysis buffer was added to the 
pellet; which was vortexed and centrifuged at 14 000 rpm for 15 minutes. The supernatant was 
carefully discarded and the pellet was re-suspended with 1ml cold phosphate buffer saline 
(tablet) and vortexed briefly. The samples were centrifuged at the same conditions as the 
previous step and the resulting supernatant was carefully discarded. The pellet was re-
suspended with 500 μl cold lysis buffer (0.01 M Tris, 0.4 M NaCl and 0.002 M EDTA), 10% 
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SDS and 3 μl 20 mg/ml Proteinase K (Thermo Fisher Scientific, Weltham, Massachusetts, 
United States); the samples were incubated at 56°C overnight.  
 
To precipitate the DNA, 200 μl of 6M NaCl was added to the tube containing the overnight 
sample and solute mixture; and then vortexed for 15 seconds. The samples were centrifuged at 
5 000 rpm for 15 minutes and the supernatant was transferred into a clean 1.5 ml Eppendorf 
tube. One volume of isopropanol was added to the supernatant and the tubes were inverted 
gently until the solution was clear; the samples were then incubated at -80ºC for 30 minutes. 
DNA was then pelleted by centrifugation at 14 000 rpm for 30 minutes and the pellet was 
washed with 100 μl of 70% Ethanol followed by centrifugation at 14 000 rpm for a further 15 
minutes. The pellets were dried briefly at room temperature and then re-suspended in a final 
volume of 30μl nuclease free water. The concentration of DNA yielded was quantified using a 
Nanodrop ND 1000 Spectrophotometer (Thermo Fisher Scientific, Weltham, Massachusetts, 
United States) and the samples were immediately stored at -20°C for future use. 
 
3.5. Reverse Transcription and cDNA synthesis 
In order to study RNA downstream, a conversion from RNA to a complementary DNA (cDNA) 
strand is required since amplification methods works with the double stranded DNA. The RNA 
provides a template from which the cDNA is reverse transcribed by the enzyme reverse 
transcriptase.  RNA concentrations determined with Agilent® 2100 Expert Bioanalyzer™ 
(Agilent Technologies Santa Clara, California, United States) were used to calculate the 
starting RNA volume in order to have starting concentration of 100ng/μl.  
Residual genomic DNA was removed using the QuantiNova™ Genomic DNA removal 
components (Qiagen, Venlo, Netherlands) according to the manufacturer’s manual. Each RNA 
sample was aliquoted into a 200 μl tube in a 100 ng/μl concentration containing (2 μl of gDNA 
removal and RNAse inhibitor mix) made up to 15 μl with RNase-free water. The samples were 
incubated at 45oC for 2 minutes then placed on ice immediately to remove excess genomic 
DNA.  
Complimentary DNA (cDNA) was synthesized using the QuantiNova™ Reverse Transcription 
Kit (Qiagen, Venlo, Netherlands) according to the manufacturer’s protocol. A master mix was 
prepared containing 1 μl of the Reverse transcription enzyme and 4 μl of reverse transcription 
mix for each sample; which was added to the genomic removal reaction. The samples were 
placed on the 2720 Thermal cycler (Applied Biosystems, Scientific, Weltham, Massachusetts, 
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United States); cDNA synthesis occurred under the following cycling conditions, annealing at 
25oC for 3 minutes, reverse transcription at 45oC for 10 minutes and enzyme inactivation at 
85oC for 5 minutes. The cycler’s lid was kept open to avoid vaporization; thereafter the samples 
were immediately placed on ice. 
 
3.6. Real Time Quantitative Polymerase Chain Reaction  
The use of real time quantitative polymerase chain reaction (RT-qPCR) in molecular biology 
has become an important tool with various applications including disease diagnosis. RT-qPCR 
is an essential quantitative method that is used to detect the expression of RNA transcripts 
through two techniques namely one-step or two-step reactions. In one-step reaction the reverse 
transcription and quantification occurs sequentially in one tube under optimized reaction 
conditions, whereas two-step reaction has the reverse transcription and quantification occurring 
in separate tubes under optimized conditions (Santos et al., 2004). For the purpose of this study 
the two-step technique was used.  
RT-qPCR was carried out on the ABI 7900HT Fast Real Time PCR system (Applied 
Biosystems, Weltham, Massachusetts, United States); amplification was performed using the 
QuantiNova™ SYBR® Green RT-qPCR kit (Qiagen Venlo, Netherlands).  QuantiTect® Primer 
Assays (RET ENSG00000165731, EDNRB ENSG00000136160, SOX10 ENSG00000100146 
and NRG1 ENSG00000157168) and the endogenous controls HPRT ENSG00000165704 and 
HSP (Qiagen Venlo, Netherlands) were used for amplification according to the manufacturer’s 
protocol. The components of the RT-qPCR are listed in table 3.2. Cycling conditions for RT-
qPCR were set as follow: heat activation at 95oC for 2 minutes, 40 cycles of 2-step cycling: 
denaturation at 95oC for 5 seconds and annealing/extension at 50oC for 10 minutes. All sample 
reactions were performed in triplicate. 
Table 3.2: RT-qPCR components and volume of each component used for the real time 
amplification of the HSCR cohort samples 
 
Component 384 well volume Final Concentration 
2x QuantiNova SYBR Green RT-
PCR Master Mix 
5 μl  1x 
QN ROX Reference Dye (Applied 
Biosystems cycler only) 
0.05 μl 1x 
10x primer mix  1 μl 1x 
Template RNA  Variable 100 ng/μl reaction 
RNase-Free Water Variable  - 
Final Volume 10 μl  
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3.7. Polymerase Chain Reaction (PCR) 
Standard PCR is a technique used for the amplification of DNA under the action of the enzyme 
DNA polymerase. It uses one strand of the DNA as a template meanwhile the enzymes adds 
deoxyribonucleotide triphosphates (dNTPs) to the growing strand. This method is widely to 
amplify specific regions in the genes of interest for various studies such as mutational analysis.   
Following genomic DNA extraction, the protein coding exons were amplified with primers 
designed to anneal to each of the 8 ACTG2 exons. Primers were designed using the 
PrimerQuest and OligoAnalyzer 3.1 tools (Integrated DNA Technologies®) (Table 3.3). The 
components for the PCR and their respective concentrations are shown in table 3.4. PCR 
cycling was carried out on the 2720 Thermal Cycler (Applied Biosystems, Weltham, 
Massachusetts, United States) with the following parameters; 94oC for 5 minutes initialization, 
30 cycles of denaturation at 94oC for 30 seconds, annealing at 50-62oC for 30 seconds and 
extension at 72oC for 30 seconds, followed by final extension at 72oC for 7 minutes and an 
infinity hold at 4oC.  
 
Table 3.3: ACTG2 exons primers designed on the Oligo Analyzer platform, showing the 
optimised annealing temperature of each exon primer set 
Primer Sequence Purification  TA 
ACTG2-3F TTC ACA TTT CAG GGC AGA GG 25nm 
52oC 
ACTG2-3R GCTCAAAGCCTGGTGGTAT 25nm 
ACTG2-4F GTCTCCTGCTATCCTGTTTCTG 25nm 
58oC 
ACTG2-4R TGCAATAGTCCAGGGAGAGA 25nm 
ACTG2-5F GATCCATCCCATCCTGTGTAAC 25nm 
59oC 
ACTG2-5R GGCATGGACCACAGACATAG 25nm 
ACTG2-6F GGGAGTGGGTGTGGAATAAT 25nm 
58oC 
ACTG2-6R CTATACCAGCTAGGCTCACATC 25nm 
ACTG2-7F GGTAGTCAGAGCTCATTGGTAAC 25nm 
62oC 
ACTG2-7R GTCCTGAGAACTTCTTGTCCTAA 25nm 
ACTG2-8F GGTTGCAGTGAGCCAAGATAG 25nm 
60oC 
ACTG2-8R CATGACTCCTGGTGTTTCTCTC 25nm 
ACTG2-9F CGAAGAAGGGTCATTTGAGGAG 25nm 
61oC 
ACTG2-9R CAATATCATCCTGGACTGGAGC 25nm 
ACTG2-10F TGGACCACCTTGCTTATTCC 25nm 
56oC 
ACTG2-10R CCCACACAGAGAAGTAAGGC 25nm 
TA= Annealing temperature 
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Table 3.4:  Components used in the PCR amplification of the ACTG2 exons for both HSCR 
and ADL cohorts 
Component Volume per reaction Final concentration 
10x Super Therm 
Gold Taq Buffer 
12.5 μl 5x 
10mM dNTPs 2 μl 0.2 mM each 
5U/μl Super Therm 
Gold Taq 
0.075 μl 0.5U 
Forward primer 1.5 μl 10μM 
Reverse primer 1.5 μl 10μM 
Template DNA Variable 100 ng/μl 
Nucleated water Variable  - 
Final Volume 25 μl  
 
 
3.8. Agarose gel electrophoresis 
Agarose gel electrophoresis is a widely used method of visualizing biological macromolecules 
which employs intercalating dyes to enable visualization. It separates DNA/RNA according to 
size while using the electric current applied on the gel to move the molecules, the smaller 
fragments migrate quicker and end up at the bottom of the gel and the larger molecules migrate 
slower and occupy the top region of the gel. This technique is used as a qualitative method to 
either check for amplification post PCR or the size of fragments digested and undigested. Here 
it was used to check for successful amplification post PCR.  
Post amplification, the samples were checked for successful amplification by gel 
electrophoresis at 100V on a 1% agarose gel prepared with 1x SB (di-sodium tetraborate 
decahydrate) buffer and stained with 1.5 μl ethidium bromide. Samples were loaded onto the 
prepared gel in 4 μl volume with 2 μl of 6x DNA Gel loading dye (ThermoFischer Scientific, 
Weltham, Massachusetts, United States). A 1kb DNA ladder (Kapa biosystems, Salt River, 
Cape Town, South Africa) loaded with the samples; added in 2.5 μl volumes. Visualisation of 
the gels was carried out on the GeneSnap software (SYNGENE, India) under ultraviolet light 
illumination. 
 
3.9. Sequencing 
To determine the order of the nucleotides on a gene of interest sequencing is carried out on the 
PCR product which is subjected to a detection by synthesis method known as Sanger 
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sequencing. The nucleotide bases give off fluoresce upon incorporation into the complimentary 
strand of the cloned gene segment which is detected and read as a chromatograph.  
Samples that were successfully amplified with the PCR technique were purified and sequenced 
bidirectionally on the ABI 3730xl/3500xl DNA Sequencer (Applied Biosystems, Weltham, 
Massachusetts, United States) at CAF and Inqaba biotech using the ACTG2 primers spanning 
the intron-exon boundaries. The sequences were analysed on the FinchTV 1.4.0 chromatograph 
viewer (Geospiza, Inc.). 
 
3.10. In Silico analysis 
3.10.1. Pathogenicity prediction 
Prediction tools are used in research to further determine the effects of novel SNPs in silico, 
the algorithm of the tools use scores to rank SNPs based on sequence conservation, genic 
effects and regulatory element annotations (Rentzsch et al., 2019). Numerous tools are 
available which include but not limited to Sorting Intolerant From Tolerant (SIFT), PolyPhen-
2, MutationTaster and Combined Annotation Dependent Depletion (CADD), newly identified 
SNPs are considered significant or non-significant based on these prediction scores. Where 
benign is classified as score from 0-0.68, possibly damaging from 0.7-0.89 and probably 
damaging from 0.9-1.00 by PolyPhen-2. CADD uses a scaled score known as PHRED-like 
which is a log10 where benign is any value from 0-15 and deleterious is a value above 20 
(Kircher et al., 2014; Rentzsch et al., 2019). Meanwhile SIFT utilizes sequence homology 
within species in order to predict if a nucleotide base exchange will affect the resulting protein 
function, its scoring method categorizes  SNPs as either tolerated with a score greater than 0.05 
or deleterious with a score equal or less than0.05 (Pauline and Henikoff, 2003). 
Novel ACTG2 variants observed on the sequences were tested on the Hope 1.1.1 (Center for 
Molecular and Biomolecular Informatics) http://www.cmbi.ru.nl/hope  for changes in the 
amino acids. They were further tested for pathogenicity on PolyPhen-2 
http://genetics.bwh.harvard.edu/pph2/, MutationTaster http://www.mutationtaster.org, SIFT 
http://sift.bii.a-star.edu.sg/www/SIFT_seq_submit2.html and CADD 
https://cadd.gs.washington.edu/snv;  the species conservation of the ACTG2 was tested on the 
CLUSTALW (Kyoto University Bioinformatics Center) platform. 
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3.10.2. Secondary structure prediction 
SWISS MODEL (The Center for Molecular Life Sciences, University of Basel) 
https://swissmodel.expasy.org/interactive was used to model the variants observed on the 
ACTG2 exons and visualize the possible structural change on the protein. Additionally, Self-
Optimized Prediction from Multiple Alignment (SOPMA) (Institut de Biologie et de Chimie 
des Protéines, UPR 412-CNRS, Lyon, France) https://npsa-prabi.ibcp.fr/cgi-
bin/npsa_automat.pl?page=/NPSA/npsa_sopma.html was used to predict the secondary 
structure modifications of the mutants. 
 
3.10.3. Human Splicing Finder 
In order to study the potential effect of SNPs occurring in the intronic boundaries of eukaryotic 
cells, the Human Splicing Finder (HSF) algorithm was developed (Ohno et al., 2018). It’s 
function of assigning the significance of splice sites is based on categorizing them into one of 
the 2 groups; namely exonic splice silencer (ESS) which are cis-regulatory elements that inhibit 
use of adjacent splice sites or exonic splice enhancer (ESE) which promote regulated and 
constitutive splicing (Desmet et al., 2009; Grodecká et al., 2017). Homozygous variants that 
were observed in the intronic regions of ACTG2 were tested for possible interfering with the 
splice sites of the gene using HSF (Bioinformatics & Genetics Team, Aix Marseille Université) 
http://www.umd.be/HSF3/. 
 
3.10.4. PyMOL  
Visualization of compounds is essential in the study of macromolecules especially in the 
prediction of bonds between compounds. PyMOL provides such a platform for molecular 
docking, binding site analysis and 3D virtual analysis of biological macromolecules (Chaudhari 
and Li, 2015; Seeliger and de Groot, 2010). The identified variants were modelled on the 
PyMOL 2.2 (Schrödinger, Inc.) to further predict their effect on the protein structure. 
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CHAPTER 4 
4. Results 
 
4.1. HSCR ENS genes 
4.1.1. Preliminary mapping of candidate genes 
Genes selected for the study of quantitative expression in the HSCR cohort were shown to be 
co-expressed in the gene interaction network generated with GENEMania, illustrated by figure 
4.1. EDNRB is associated with melanocyte development; it is shown to be co-expressed with 
both SOX10 and RET in figure 4.1 SOX10 is also linked to the development of melanocyte. 
Whereas, NRG1 which is known to be involved in melanocyte development does not share a 
pathway with either SOX10 and EDNRB, resulting from their localization within the cell. NRG1 
is located within the mesenchyme whereas EDNRB and SOX10 are both located in the nucleus 
(figure 2.3). Thus, NRG1 mechanism of action in melanocyte development may be achieved 
through a different pathway.  
Whilst SOX10 has been shown to have a direct effect on both EDNRB and RET as a 
transcription factor, none of the genes of interest on figure 4.1 are shown to directly share 
biological pathways. Co-expression of these genes is linked to their biological processes in 
ENS development, although they achieve it through different pathways.  
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Shared pathway 
Co-expression 
 
 
 
 
 
 
 
 
 
 
Figure 4.1: Protein association network of the HSCR genes of interest generated with 
GENEMania, showing the genes co-expression and shared pathways   
 
4.1.2. Quantitative expression  
Eight samples were chosen for RT-qPCR amplification, these were samples with RNA 
concentration above 80 ng/μl and RNA integrity (RIN) value above 7 based on the Bioanalyzer 
and Nanodrop RNA quantification shown in table 4.1. Protocol optimization of the RT-qPCR 
was performed using RNA sample not from the study cohort, by amplification of the genes of 
interest (EDNRB, SOX10, NRG1 and RET) under the conditions outlined in Chapter 3, 3.5 and 
3.6.  Following this result, the first run of the RT-qPCR was carried out; and the temperature 
cycling worked, however further optimisation was required to successfully amplify the patient 
samples.  
Figure 4.2 illustrates an amplification plot of the selected HSCR genes of samples HD6,9-14 
showing the number of cycles on the x axis and the reporter value on the y as a log- measure. 
From the entire sample set only 2 samples reached the amplification threshold within 18 cycles; 
the other samples reached their threshold well after 30 cycles. The amplification plot shows 
non-specific binding; contrary to what is expected of a successful RT-qPCR; it produced data 
with very high cycle threshold (Ct) values as illustrated by figure 4.2. Repeats of the protocol 
with increased sample RNA, yielded the same results. RNA samples HD14-17 were not 
quantified on the Bioanalyzer (table 4.1). 
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Table 4.1: HSCR samples showing the RNA concentration quantified with the NanoDrop and 
Bioanalyzer machines and their respective RIN value  
Sample 
Concentration 
(NanoDrop) 
Concentration 
(Bioanalyzer) 
RIN value 
HD03 157.6ng/μl 126.8 ng/μl 2.7 
HD06 139.8 ng/μl 178 ng/μl 10 
HD07 23.6 ng/μl 37 ng/μl 9.80 
HD08 50.0 ng/μl 49 ng/μl 9.30 
HD09 72.4 ng/μl 98 ng/μl 9.70 
HD10 88.0 ng/μl 85 ng/μl 10 
HD11 78.5 ng/μl 101 ng/μl 10 
HD12 101.7 ng/μl 83 ng/μl 10 
HD13 160.8 ng/μl 217 ng/μl 10 
HD14 303.1 ng/μl - - 
HD15 39.6 ng/μl - - 
HD16 38.6 ng/μl - - 
HD17 257.1 ng/μl - - 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2: RT-qPCR amplification diagram of the HSCR cohort illustrating the gene 
expression of the HSCR cohort as number of cycles on the x-axis and the normalized reporter 
value on the y-axis as a log measure  
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4.2. Smooth muscle 
HSCR cohort 
4.2.1. Smooth muscle dysmotility in HSCR patients  
Whole blood samples were collected from a total of 17 HSCR patients consisting of 13 males 
and 3 females. Fourteen samples (13 males and 1 female) were screened for ACTG2 mutations; 
the other 3 samples were excluded based on the low DNA concentration and quality as 
determined by the Nanodrop quantification. Variants identified in the study cohort were single 
base non-synonymous exchanges occurring in the 8 protein coding exons (exon 3-10) such as 
the one shown in figure 4.3; these were studied further in silico to investigate their effects on 
the ACTG2 protein model. Figure 4.3 shows a chromatograph of one of the HSCR patients 
with the ACTG2 S345L mutation shown by the dotted box around a homozygous SNP, the 
variant shows both C and G codons occurring at the same position.  
 
 
 
 
 
Figure 4.3: Amino acid chromatograph showing the S345L mutation occurring on the ACTG2 
exon 10 of one of the HSCR patients analysed on FinchTV 
 
ACTG2 variants observed in the HSCR cohort are outlined in table 4.2; these included known 
and new amino acid coding and intronic variants.  c>t -IVS6 on exon 3 and T>G V160R on 
exon 7 are known variants classified as SNPs without clinical significance by Single Nucleotide 
Polymorphism database (dbSNP) rs1050146 and rs761385269 respectively; T>G V160R was 
sequenced on the reverse strand with the annotation V160L. Newly identified SNPs were 
considered significant or non-significant based on the SIFT, PolyPhen-2 and CADD 
pathogenicity prediction scores. Where benign 0-0.68, possibly damaging 0.7-0.89 and 
probably damaging 0.9-1.00 by PolyPhen-2. Deleterious >20> benign by scaled CADD, and 
deleterious <0.05< tolerated by SIFT shown on table 4.4. Intronic SNP g>c -IVS12 which 
occurred on exon 3 was observed in 4 patients, this SNP was studied further in silico and 
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classified as a polymorphic SNP by MutationTaster.  It was predicted to modify exonic splice 
site by both MutationTaster and HSF; its effect was predicted to create an exonic splice silencer 
which shifts the splice site.  
Other variants, L217A and L243P were considered non-significant as a result of the PolyPhen-
2 scores 0.508 and 0.172 respectively shown in table 4.4. Although L217A was also placed 
within the 10% most deleterious variants by the scaled CAAD score of 10.73. L243P variant 
was observed in 1 patient whereas L217A was identified in 2 patients. Another variant 
considered non-significant was the V153C variant observed in 2 patients of the study cohort. 
It was classified as pathogenic by both PolyPhen-2 and SIFT; it may be significant considering 
these scores, although CADD ranked it as non-pathogenic. 
Meanwhile, nonsynonymous amino acid change from a lysine (Lys/K) to glutamic acid (Glu/E) 
or arginine (R) on amino acid residue position 119 (K119E/R) were observed in the majority 
of the samples; 9 out of 13 patients and 6 out of 9 control samples (tables 4.2 and 4.3). The 
SNP was predicted to be benign by PolyPhen-2 score of 0.373; however, it was predicted to be 
within the top 10% of most deleterious SNP by CADD with a score 13.43. In addition, SIFT 
predicted the SNP to be pathogenic as shown in table 4.4 with a 0.00 score and a median species 
conservation score of 3.15; this may be the consequence of the high sequence conservation in 
the ACTG2 protein amongst species as shown by the species conservation phylogenetic tree 
(appendix figure 7.1) predicted by the CLUSTALW platform. Moreover, at position 119 
another variant exists K119Q which has been identified and characterised on dbSNP 
rs747545226; the variant is predicted to be of no clinical significance. 
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32 
rs =accession number, dbSNP 
WT= Wild Type 
> = base exchange/substitution 
Table 4.2: Known and novel ACTG2 variants observed in the HSCR cohort
Sample Exon3 Exon4 Exon5 Exon6 Exon7 Exon8 Exon9 Exon10 
HD03 WT WT 
c.171 A>G 
K119E 
WT WT c.221G>C L217A WT 
c.108 T>G 
W357G 
HD05 c.134 g>c -IVS12  WT 
c.171 A>G 
K119E 
WT WT c.221G>C L217A WT c.109C>G S345L 
HD06 c.134 g>c -IVS12  WT 
c.171 A>G 
K119E 
WT WT WT WT c.109C>G S345L 
HD07 WT WT WT WT WT WT WT WT 
HD08 c.134 g>c -IVS12  WT 
c.171 A>G 
K119E 
WT 
c.81T>G V160R  
rs761385269 
WT WT c.109C>G S345L 
HD09 WT WT 
c.171 A>G 
K119E  
WT WT WT WT c.109C>G S345L 
HD10 WT WT WT WT WT WT WT c.109C>G S345L 
HD11 
c.74 c>t -IVS6 
rs1050146 
WT 
c.171 A>G 
K119E 
WT WT c.300 G>C L243P WT c.109C>G S345L 
HD12 WT WT WT WT WT WT WT WT 
HD13 WT WT 
c.175 A>G 
K119R                 
WT c.62 T>C V153C WT WT WT 
HD14 
c.74 c>t -IVS6 
rs1050146  
WT 
c.171 A>G 
K119E 
WT WT WT WT WT 
HD15 
c.74 c>t -IVS6 
rs1050146  
WT 
c.171 A>G 
K119E  
WT WT WT WT WT 
HD16 WT WT WT WT WT WT WT WT 
HD17 c.134 g>c -IVS12  WT WT WT c.62 T>C V153C  WT WT WT 
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rs =accession number, dbSNP 
WT= Wild Type 
> = base exchange/substitution 
Furthermore, the variant K119E/R was also observed in the healthy control cohort (figure 4.3); 
supporting the rationale that the variant is possibly not directly involved in the disease 
pathogenesis. It may be essential to the enteric smooth muscle pathophysiology as a disease 
modifier instead; considering that all the HSCR patients observed with possibly pathogenic 
variants also carried this variant. Figure 4.4 depicts a modelled tertiary structure of the variant 
K119E; showing no possible effect on the other amino acids within close bonding distance on 
the tertiary structure of ACTG2. The amino acid exchange is non-conservative changing a basic 
residue Lys to a polar uncharged residue Glu; predicted to have little to no effect on the protein-
protein interaction. The healthy control cohort also had the intronic SNP c>t -IVS6 rs1050146 
determined by literature to be clinically insignificant.  
 
 Table 4.3: ACTG2 screening of the healthy control samples observed to have the intronic C>T 
-IVS6 and K119E/R variants 
 
 
 
Two SNPs of interest observed in the HSCR cohort namely T>G W357G and C>G S345L were 
both observed in exon 10 of ACTG2; both SNPs were predicted to be damaging by all the 
prediction networks used as shown in table 4.4.  Based on this they were studied further in 
Sample Exon3 Exon4 Exon5 Exon6 Exon7 Exon8 Exon9 Exon10 
NC1 WT WT 
c.174 A>G 
K119E 
WT WT WT WT WT 
NC2 
c.74 C>T -IVS6 
rs1050146 
WT WT WT WT WT WT WT 
NC3 WT WT 
c.176 A>G 
K119R 
WT WT WT WT WT 
NC4 
c.74 C>T -IVS6 
rs1050146 
WT WT WT WT WT WT WT 
NC5 WT WT WT WT WT WT WT WT 
NC6 WT WT 
c.176 A>G 
K119E 
WT WT WT WT WT 
NC7 WT WT 
c.176 A>G 
K119E 
WT WT WT WT WT 
NC8 WT WT 
c.176 A>G 
K119E 
WT WT WT WT WT 
NC9 
c.74 C>T -IVS6 
rs1050146 
WT 
c.176 A>G 
K119E 
WT WT WT WT WT 
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silico to elucidate the effects they may have on the ACTG2 protein and possibly the enteric 
smooth muscle etiopathogenesis in Hirschsprung’s disease patients. 
 
Table 4.4: ACTG2 single nucleotide polymorphisms (SNPs) identified in HSCR patients 
showing the pathogenicity score as predicted by the nsSNP predictor tools, the number of 
patients affected and the exon which each variant occurs 
*msc = Median sequence conservation 
 
 
 
 
 
 
 
 
Figure 4.4: Tertiary structure modelling of the ACTG2 K119E variant and the neighbouring 
amino acid residue in close bonding distance; showing the variant Glu in cyan, Lys at position 
114 and 117 in green and Trp at position 80 in magenta generated with PyMOL 
 
4.2.2. Secondary structure predictions 
ACTG2 SNPs S345L and W357G were not present in the control sample set and were thus 
chosen for further analysis. In silico analysis with scaled CADD PHRED of S345L and W357G 
resulted in pathogenicity prediction scores of 25.8 and 33 respectively presented in table 4.3, 
thus the variants were predicted to be probably disease causing based on these scores. S345L 
Variant Exon  # PolyPhen-2  SIFT (msc)  (CADD) 
K119E/R 5 9 0.373 0.00 (3.15) 13.43 
V153C 7 2 1.00 0.00 (3.15) 4.6 
V160R 7 1 0.74 0.05 (3.15) 6.73 
L217A 8 2 0.508 0.00 (3.15) 10.73 
L243P 8 1 0.172 0.00 (3.15) 4.5 
S345L 10 6 0.99 0.00 (3.15) 25.8 
W357G 10 1 0.97 0.00 (3.12) 33 
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A B 
variant occurred by a homozygous single base substitution as illustrated by the boxed in region 
of figure 4.3. In silico modelling with SWISS model predicted structural changes on the non-
synonymous mutation S345L where the wild type is shorter as depicted on figure 4.5 A 
compared to the longer side chain of the mutant shown in figure 4.5 B. This SNP was observed 
in 46% (6 out of 14) of the study cohort whereas the control samples were all wild type.  
Furthermore, the mutation resulted in an altered secondary structure of the protein by 
substitution of an uncharged; polar Serine (Ser/S) with a non-polar hydrophobic Leucine 
(Leu/L). The substitution from Ser to Leu introduces an amino acid change from a neutral and 
small amino acid into a hydrophobic residue, this change alters the secondary structure due to 
the properties of Leu which prefers to be buried within the core of the protein unlike Ser. Amino 
acid Ser is located on a helical structure on the ACTG2 protein; hence, changing the residue 
may affect the protein folding into its tertiary structure and subsequently the quaternary 
structure. Secondary structure prediction with SOPMA showed that the wild type has a coil 
which is adjacent an alpha (α) helix on the protein sequence; meanwhile the mutant produces 
an extended strand instead. 
 
 
 
 
 
 
 
 
 
Figure 4.5: Protein structure prediction model of the ACTG2 variant S345L generated with 
SWISS Model showing the wild type with a shorter side chain (A) and the mutant with an 
extended side chain (B) also showing the amino acids Ser and Leu localization on the protein  
 
A heterozygous base change from T to G on exon 10 shown in figure 4.6 resulted in a variant 
W357G in one of the patients.  W357G is also a non-conservative variant which has an amino 
Stellenbosch University  https://scholar.sun.ac.za
36 
 
acid replacement from an aromatic Tryptophan (Trp/W) to a small Glycine (Gly/G); this amino 
acid change subsequently changes the conformation from a short beta (β) strand into a β-turn 
as predicted by SOPMA.Figure 4.7 illustrates the modelled structure of the wild type A and 
variant B; the aromatic ring of the wild type Trp is substituted by a Gly in the mutant which is 
considerably small compared to the Trp. Secondary structure prediction of the ACTG2 protein 
also showed the amino acid W to be preceded by an α-helix that is followed by a coil, these are 
abolished by the amino acid residue substitution.  
 
 
 
 
 
 
Figure 4.6: Amino acid chromatograph illustrating a heterozygous base exchange T>G on 
ACTG2 exon 10 producing the W357G variant analysed on FinchTV 
 
 
 
 
 
 
 
 
 
 
Figure 4.7: Protein modelling of the ACTG2 variant W357G showing the wild type with an 
aromatic side chain Trp (A) and the mutant with a short Gly side chain (B) generated with 
SWISS Model 
 
B A 
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Furthermore, Trp is an aromatic residue known to carry pi (π) electrons which interact in 
covalent bonds such as ring stacking with other aromatic residues or cation bonds with basic 
residues; the bonds are therefore affected by non-conservative amino acid substitution due to 
the π electrons reactivity. Residue interaction within bonding distance of the Trp wild type 
showed it to have close interaction with Phenylalanine (F) on position 353 and Tyrosine (Y) 
on position 134 illustrated in figure 4.8. Y134 residue is a known visceral myopathy variant . 
Taken together these data suggest that the mutation W357G may have a significant effect on 
the aetiology of the enteric smooth muscle in Hirschsprung’s patients carrying this mutation. 
 
 
 
 
 
 
 
 
Figure 4.8: Modelled secondary structure of ACTG2 protein generated with PyMOL showing 
the wild type aa residue W on position 357 in red and neighbouring amino acid residues F353 
in yellow and Y134 in cyan within bonding distance of each other   
 
ADL cohort 
4.2.3. Smooth muscle degeneration in ADL patients  
Variants observed in the 5 ADL patients did not include known Visceral SCM SNPs; table 4.5 
displays all the variants identified in the ADL cohort including the exon in which they occur. 
Variant K119E/R was also identified in the ADL patients occurring together with homozygous 
amino acid base exchange occurring at the intronic regions (figure 4.9). The variant K119E/R 
occurring on exon 5 was observed in 3 patients which also had the intronic variants t>c-IVS3 
on the same exon/intron boundary and t>c +IVS16 post exon 7. Meanwhile g>c -IVS12 also 
occurred in 3 patients together with t>c +IVS16 variant in 1 patient.  
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Figure 4.9: Exonic splice silencer g>c -IVS12 on the intronic region prior to exon3 of ACTG2; 
showing a homozygous variant with G and C bases at the same position analysed on FinchTV 
 
These variants were unique and occurred prior to exon 3 and 5 g>c -IVS12 and t>c-IVS3 
respectively. The other intronic variant was a splice site acceptor occurring post exon 7 t>c 
+IVS16 shown in table 4.5. Table 4.6 shows the predicted effects of the variants in the ADL 
cohort and the exons in which they were observed on. Variants g>c -IVS12 and t>c-IVS3 are 
splice site donors predicted to be polymorphic variants; which are capable of causing a shift in 
the splice sites located in these regions. Both g>c -IVS12 and t>c-IVS3intronic SNPs create 
exonic splice silencers; which inhibit the splicing of introns prior to mRNA translation.  
 
 Table 4.5: ACTG2 variants observed in the ADL cohort, showing the observed variants and 
the exons they occur in 
 
 
Sample  Exon3 Exon4 Exon5 Exon6 Exon7 Exon8 Exon9 Exon10 
ADL01  WT WT 
c.463 A>G 
K119R, c.74 
t>c-IVS3 
WT 
c.236 t>c 
+IVS16 
WT WT WT 
ADL02  
c.134 g>c         
-IVS12 
WT WT WT WT WT WT WT 
ADL03  
c.134 g>c         
-IVS12 
WT WT WT WT WT WT WT 
ADL04  
c.134 g>c          
-IVS12 
WT 
c.463 A>G 
K119E, c.74 
t>c-IVS3 
WT 
c.236 t>c 
+IVS16 
WT WT WT 
ADL05  WT WT 
c.463 A>G 
K119E, c.74 
t>c -IVS3 
WT 
c.236 t>c 
+IVS16 
  WT   WT WT 
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K119E/R and t>c -IVS3 have the same CADD value 13.43 which places both variants in the 
10% of the most deleterious mutations; a prediction score which is in agreement with the other 
in silico analysis predicting the variants to be possibly pathogenic. Although g>c -IVS12 has 
been predicted to be a polymorphic splice site changing variant; its CADD score is below 1, 
predicting the variant to be benign. The inverse is true for t>c +IVS16 which is predicted to 
have no effect by MutationTaster; whereas its scaled CADD score is within the 10% most 
deleterious mutations.  
 
 
Table 4.6: ACTG2 SNPs identified in the ADL cohort, showing the pathogenesis prediction 
scores of each variant, the exon of occurrence and the number of patients affected 
Variant Exon MutationTaster HSF CADD 
K119E 5 - - 13.43 
g>c -IVS12  3 Splice site change ESS 0.258 
c>t -IVS3  5 Splice site change ESS 13.43 
t>c +IVS16  7 No effect ESS 10.95 
ESS = Exonic splice silencer 
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CHAPTER 5 
5. Discussion 
 
5.1.1. Gene expression analysis of HSCR 
HSCR is regarded as one of the most common paediatric gastrointestinal disorders affecting 
the colon. Its aetiology is associated with multiple genes involved in ENS development of 
which the RET proto-oncogene is regarded as the central gene (Carter et al., 2012). Various 
genes associated with the HSCR phenotype have been discovered through whole exome 
studies; although for some genes their functional properties have not been validated (Gui et al., 
2017). Quantitative studies such as RT-qPCR are essential to provide further insights into the 
disease mechanism. This study was aimed at providing such a validation of correlating the 
observed HSCR phenotype and expression of certain genes associated with ENS development, 
through quantitative analysis of the genes of interest RET, EDNRB, NRG1 and SOX10 shown 
to have a molecular correlation (Alves et al., 2013). The HSCR study cohort was made up of 
13 males and 1 female following one of Hirschsprung’s disease characteristics of a male 
predominance.  
Although RNA quality obtained from the study participants was acceptable and the RIN values 
for the selected samples were well above the minimal 7; the experiment produced low copy 
number of each sample which resulted in very high Ct values based on the set threshold, these 
are then classified as non-detects (McCall et al., 2014). These may be caused by other factors 
including the quality and quantity of the sample RNA and the interference from the SYBR 
green dye or the primer assays. The selected genes of interest RET, EDNRB, NRG1 and SOX10 
each have numerous transcripts of which may promote non-specific binding of the primers in 
reaction this can be seen by the delayed amplification on the amplification plot. The 
housekeeping genes (HPRT and HSP) were also not amplified Primer assays are designed to 
anneal to the template at certain optimal temperatures and to specific sequences; the possibility 
of more than one transcript may affect their annealing efficiency of the primer assays.  
SYBR green on the other hand is an intercalating dye known to bind to double stranded DNA 
(Gudnason et al., 2007) with high affinity; should the conversion of RNA to cDNA not occur 
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efficiently it consequently affect the quantification which may have been the case in this study. 
In addition, Giglio and colleagues reported that SYBR green has preferential binding to certain 
DNA sequences (Giglio et al., 2003); which may be the cause of the amplification of some 
samples over others as shown by the amplification plot . Therefore, a conclusion regarding the 
correlation between the phenotype and genotype of the commonly reported genes involved in 
ENS development RET, EDNRB, NRG1 and SOX10 in confirmed HSCR patient was not 
reached. 
 
5.1.2. HSCR and ACTG2 genetic factors 
Post-operative complications such as bowel obstruction, anastomotic leakage, faecal 
incontinence and perineal excoriation have been reported in at least 32% of HSCR patients 
(Jarvi et al., 2010). This evidence suggests that HSCR may be a result of not only ENS 
pathogenesis; in some affected patients it may be a result of a combination of muscular and 
neuronal dysfunction. The slow gastric transit experienced by some HSCR patients post 
resection surgery can be correlated to slow enteric muscular contraction resulting from smooth 
muscle deficit (Faure et al., 2016). Gastrointestinal motility is a functional consequence of a 
well-coordinated contraction by muscle layers of the alimentary canal, neuronal current which 
require an intact neuronal network and muscular layers (Sanders et al., 2012) and the 
pacemaker ICC.  
In this study ACTG2 which has been associated with the aetiology of visceral myopathy was 
investigated in patients with histologically confirmed HSCR. Actin forms part of the support 
and maintenance of the cytoskeleton; these are highly conserved proteins within species as 
illustrated by the species conservation phylogenetic tree on the appendix figure 7.1. Although 
actins are found throughout the body, gamma actins are exclusively found in the enteric portion 
of the body. Through the prospective study of the HSCR cohort the S345L and W357G SNPs 
were observed in 6 and 1 patient/s respectively; interestingly they were both absent in the 
control cohort. Both mutations are novel and non-conservative; they were predicted to alter the 
secondary structure of the ACTG2 protein and are possibly disease causing.  
Variants S345L and W357G are categorized by scaled CADD to be in the 1% and 0.1% most 
deleterious substitutions respectively as shown in table 4.4. As a result, they cannot be 
overlooked as the essential smooth muscle genetic factors that may contribute to the HSCR 
pathogenesis. It was further observed that W357G occurred to have bonds with a known VSCM 
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variant Y134 rs587777388 , which has been identified in numerous familial cases as a de novo 
missense variant (Thorson et al., 2014; Wangler et al., 2014). In addition to the exon 10 
variants; another variant was observed in the HSCR cohort occurring on exon 5 K119E/R. 
K119E/R is also a non-conservative variant; although it was also observed in the healthy 
control. Consequently, due to the presence of this variant in both the HSCR patients and healthy 
controls it was deemed as non-significant in disease pathology; however, it may play a role as 
a disease modifier since the patients that harboured the exon 10 variants S345L and W357G 
also had the K119E/R variant.  The importance of K119E/R is demonstrated by a scaled CADD 
score of 13.43 as shown in table 4.4; which is within the 10% most deleterious substitutions 
and can therefore be considered to play a role in disease pathogenesis.  
Additionally, other variants namely V153C, V160R, L217A, L243P and intronic variant c>t -
IVS6 were observed in the HSCR cohort. However, these were considered as non-significant 
and not pathogenic based on their pathogenicity score predictors; which were below the value 
of significance as specified by PolyPhen-2 and CADD. Although V153C and L217A were 
predicted to be pathogenic by PolyPhen-2 and scaled CADD respectively; they were not 
investigated further since they were each predicted to be pathogenic by only one platform. The 
use of in silico prediction algorithm to determine whether as SNP is deleterious is dependent 
on the information available on the tool; mainly the quality of the multiple sequence 
alignments. It has been reported that most in silico prediction algorithms use paralogue protein 
sequences to predict the effect of amino acid changes instead of a combination of both 
paralogues and orthologues (Wong and Zhang, 2014). Hence the use of more than one 
prediction tool is essential in determining the role on the SNP on the protein.   
 
5.1.3. Genetic basis of ADL 
Research in HSCR patients focuses solely on factors that control genes involved in ENS 
development; Gui and colleagues 2017, revealed that ENS genes and variants substantiate only 
up to 25% of the HSCR genetic risk (Gui et al., 2017). Thus, studying other genes involved in 
the gastroenteric pathway such as the smooth muscle ACTG2 may provide relevant information 
regarding the disease etiopathogenesis. Although the smooth muscles develop and produce 
slow autonomous contraction independent of the ENS; their development occurs in parallel 
proving the existence of their poorly understood developmental correlation. This is the first 
study conducted on this smooth muscle cell gene of HSCR patients and has been submitted to 
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the Paediatric Surgery International journal; currently under review (Chapter 7, article 2). 
(Graham et al., 2017)  
ADL affects children of Central, Southern and East African descent; it is therefore fitting to be 
referred to as African degenerative leiomyopathy. ADL forms part of the visceral myopathy 
spectrum. Unlike VSCM its etiopathology has been linked to environmental factors that 
deteriorate the muscles of the distal part of the alimentary canal; which leads to an enlarged 
abdominal area (Rode et al., 1992). Numerous reports of ADL have been isolated; although, 
RET promoter variants in familial ADL have been observed. The discovery of RET variants in 
a familial ADL study, initiated interest in the prospective study of genes in patients affected 
with ADL (Van Rensburg et al., 2012). Studying the ACTG2 gene associated with VSCM 
which exhibits similar phenotype in affected individuals may provide genetic information for 
the molecular basis of the disease. 
The ADL patients were screened for variants in ACTG2. In contrast, the variants identified in 
the DNA of the study cohort selected for this research did not reveal any of the known VSCM 
variants. The variants observed were intronic polymorphisms namely g>c -IVS12 on exon 3 
and c>t -IVS3 on exon 5; predicted to have pathogenic effect by shifting the exonic splice sites. 
Furthermore, the c>t -IVS3 of exon 5 co-occurred with the dominant K119E/R variant further 
suggesting that the variant may have a disease modifying property. Although the variant g>c -
IVS12 was predicted to have an effect on the splice site of ACTG2 prior to exon 3; it was 
predicted to be tolerated by scaled CADD. The same was observed for the variant t>c +IVS16; 
which was predicted to no have an effect on the splice site by MutationTaster whereas scaled 
CADD placed it in the 10% deleterious SNPs. Such data should not be ignored hence the use 
of more than one prediction tool has proven to be essential; however they did not mitigate the 
conflicting result. Therefore, further wet bench study of these SNPs is necessary.  
This is the first study on the smooth muscle of ADL patients and the data has been published 
in the Paediatric Surgery International Journal (Chapter 7, article 1). The observation of novel 
ACTG2 SNPs in this distinct form of VSCM other than the known variants also suggest that 
ADL may affect different components of the smooth muscle cells other than the gamma actin 
cytoskeleton. In conclusion, further investigation of genetic material of patients with 
histologically confirmed ADL through whole exome sequencing could reveal other 
contributing genetic factors that lead to its aetiology. 
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5.1.4. Mutations in HSCR and ADL 
Comparing the ACTG2 SNPs observed in both HSCR and ADL cohorts there are clear 
differences in the SNPs that were identified within the two cohorts; except the polymorphic 
variant on the intronic region of exon 3 g>c -IVS12 and the probable disease modifying variant 
on exon 5 K119E/R which the cohorts shared.  This result suggests that HSCR does have a 
muscular dysfunction component; thus a conclusion may be made that the aetiopathogenesis 
of HSCR is likely associated with both neuronal and muscular genetic predispositions. 
Meanwhile ADL can be associated with both genetic and environmental predispositions. 
ACTG2 intronic variants (g>c -IVS12 and c>t -IVS3) and coding variants (K119E/R, S345L 
and W357G) observed in the study were not identified in publicly available domains viz ExAC, 
1000 Genome and dbSNP, therefore our variants can be classified as novel.   
Studying only the actin genetic factors in these patients does not provide sufficient data 
regarding the recurrence of the motility deficit in HSCR patients and the genetic basis of ADL 
pathogenesis. Further study of the myosin MYH11 in both HSCR and ADL patients may 
provide information in elucidating the underlying genetic factors that contribute to the risk of 
recurrence in motility deficit and the molecular cause of ADL; sufficient data may therefore 
provide a better model for advanced disease management strategies in both pathologies.    
 
5.2. Conclusion 
In conclusion, the results obtained in this study suggests that although ENS and smooth muscle 
development occur in parallel but independent of each other; a temporal correlation does exist 
which is not yet fully understood. γ- 2 enteric actin encoded by ACTG2 associated with familial 
visceral myopathy a known enteric smooth muscle defect; therefore, the data suggests that the 
HSCR and ADL patients with the novel ACTG2 variants may have defects in the contractile 
proteins of their enteric smooth muscles. Taken together these data opens a new field of 
research into the etiopathology of HSCR which involves the enteric smooth muscle genetic 
drivers and further provides insights into the genetic mechanism involved in the region specific 
rare gastrointestinal disease ADL.   
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5.3. Limitations  
The study had a couple of limitation evident in some of the data presented. These include the 
inability to successfully amplify and consequently prohibit the quantification of the expression 
of EDNRB, RET, SOX10 and NRG1; which may also be the result of gradual sample 
degradation due to repeated freezing and thawing. The use of RNA preserving agents such as 
RNAlater should be added to the whole blood samples immediately after collection, to aid in 
the increased yield of extracted RNA. It is known that RNA is easily degradable by RNases 
that are readily available on most surfaces. Another limitation relates to the sample size; which 
may be increased and should include sampling from other regions in South Africa; this will 
enable us to accurately elucidate the incidence of both HSCR and ADL in the South African 
population. Furthermore, it will provide enough quantity of samples to conduct a comparison 
of ACTG2 variants between the cohorts. Most of the data used in this study was generated in 
silico with various prediction and modelling platforms; although these methods are essential in 
predicting the effects of novel variants since there is no available experimental data for them, 
they are sometimes unreliable and often require more than one prediction tool to validate the 
results. 
 
5.4. Future Study 
Probes should be considered instead of primer assays and SYBR green for the quantification 
of EDNRB, RET, SOX10 and NRG1 in order to bypass the disadvantages of using these 
reagents. In addition, in vitro methods such as site directed mutagenesis should be employed 
to validate the effects of the novel variants K119E/R, S345L and W357G in a model; which is 
also essential for taking the findings further. Surveillance of HSCR patients throughout their 
life should be implemented in order to monitor if they experience recurrence of the 
aganglionosis. 
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CHAPTER 6 
Article 1 
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Recurrent ACTG2 gene variation in African degenerative visceral leiomyopathy 
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Original Article 
First Online: 15 November 2018 
 5Downloads 
Abstract 
Introduction 
Visceral myopathies remain difficult and frustrating clinical entities, a distinctive form of 
acquired degenerative visceral myopathy, African degenerative leiomyopathy, a myogenic 
functional intestinal obstruction without aganglionosis which affects smooth muscle of the 
intestine, in young indigenous African children. The Actin G2 gene is the main gene encoding 
smooth muscle actin found in enteric tissues. Recent research has identified Actin G2 alpha 
gene variation as an important causative biomarker in visceral myopathies and megacystis 
microcolon. This study of the Actin G2 gene (ACTG2) in an African population explores a 
possible molecular basis abnormal muscle function in a visceral myopathy. 
Patients and methods 
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Following ethical permission and informed consent, DNA was extracted from whole blood 
samples in five patients with histologically proven African degenerative leiomyopathy. PCR 
amplification of ACTG2 alpha gene products by semi-automated bi-directional sequencing 
analysis. Results were analysed using FinchTV Sequence Alignment Software and predicting 
bioinformatic investigation by PolyPhen-2 software. 
Results 
Five new patients with the ADL phenotypes were prospectively investigated for variation in 
the Actin G2 gamma gene (ACTG2). ACTG2 gene variation occurred in exon 5 (c.463 A>G 
K119R), in three (60%). In addition, intronic variation t  >  c-IVS3 was identified in three 
with the K119 mutation plus further g>  c -IVS12 and t  >  c  +  IVS16(2), suggesting a 
possible haplotype. Bioinformatic modelling showed that these ACTG2 gene variations are 
highly non-conservative altering protein expression. 
Conclusions 
Recurrent Actin G2 smooth muscle gene variation in African degenerative visceral 
leiomyopathy is associated with abnormal muscle actin development. 
Keywords 
Visceral myopathy African degenerative leiomyopathy ADL Children  
This is a preview of subscription content, log in to check access. 
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Is Hirschsprung disease a purely neurological condition? 
 A study of the actin G2 smooth muscle gene in Hirschsprung’s disease. 
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Hirschsprung disease is a functional obstruction of the gastrointestinal tract due to the 
congenital absence of ganglion cells in the intermyenteric plexuses of the distal bowel. 
Gastrointestinal motility requires intact muscular layers as well as neural network connection 
to function properly. The Actin G2 gene is the main gene encoding actin gamma 2; a smooth 
muscle actin found in enteric tissues.  
This study of the Actin G2 gene in patients with Hirschsprung disease explores a possible 
molecular basis abnormal muscle function and post-surgical pseudo-obstruction in a group of 
patients. As far as the authors are aware, this is the first report confirming structural muscle 
deficits in Hirschsprung disease.  
Patients and methods: Ethical permission and informed consent were obtained. DNA was 
extracted from whole blood samples in 10 patients with histologically proven HSCR patients. 
PCR amplification of the ACTG2 gene, were subjected to semi-automated bi-directional 
sequencing analysis. Sequencing results were analysed using FinchTV Sequence Alignment 
Software (http:/en.biosoft.net) to read chromatogram files. Further predicting bioinformatic 
investigation was obtained by PolyPhen 2 software to evaluate the significance of the observed 
amino acid changes. 
Results: Ten new patients with similar HSCR phenotypes were prospectively investigated for 
variation in the Actin G2 gamma gene (ACTG2) variations.  
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The results of ACTG2 gene analysis showing variation in exons 5, 8 and 10 of the ACTG2 
gene in 7 of them (64%). The c.109C>G S345L was the most frequent occurring in 6 of the 10 
patients (54%), the c.171 A>A K119E in 2 and the significant c.108 T>G W357G variation in 
exon 10 (1 patient) Four patients had a combination of different variants in different exons 
which were less significant.  
Allele frequency on a control sample of the South African population showed no comparable 
pathology link scores (http://gnomad.broadinstitute.org/). 
 
Bioinformatic in silico modelling showed that the residue replacements in both variants (Lys 
to Glu and Trp to Gly) are highly non-conservative and variation can alter interactions within 
the protein conformation.   
Conclusions: The Actin smooth muscle gene showed variation in 64% of samples, indicating 
a reason for abnormal functioning muscle in many HSCR patients. Hirschsprungs disease is 
part of a complex spectrum which also includes smooth muscle.  
 
Key words: Hirschsprung disease; enteric nervous system; smooth muscle; development; 
ACTG2 gene, mutation; intestinal motility 
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CHAPTER 7 
Appendices 
 
 
 
 
 
 
 
 
 
Figure 7.1: Mutiple sequence alignement of the ACTG2 protein of the species: human, mouse, 
horse, loxaf (Africn elephant) and myolu (little brown bat) generated with CLUSTALW  
showing  the aligment score between the species and a rooted phylogenic tree showing the 
species conservation of the protein. 
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